Last updated: February 19, 2026
This report analyzes the scope, claims, and patent landscape surrounding Canadian patent CA2720108. The patent, granted to Roche on October 20, 2015, covers Maviret (Glecaprevir/Pibrentasvir), a fixed-dose combination antiviral drug used for treating Hepatitis C virus (HCV) infection. The analysis focuses on key patent claims, their limitations, and the competitive environment of direct-acting antiviral (DAA) patents in Canada.
What is the Core Invention Protected by CA2720108?
Canadian patent CA2720108 protects a specific pharmaceutical composition containing glecaprevir and pibrentasvir. These two active pharmaceutical ingredients (APIs) are direct-acting antivirals targeting different stages of the HCV replication cycle. The patent's primary focus is on the synergistic effect and therapeutic utility of this fixed-dose combination for treating chronic HCV infection.
The invention describes the combination of:
- Glecaprevir: A protease inhibitor that blocks the NS3/4A protease, essential for viral replication.
- Pibrentasvir: An NS5A inhibitor that disrupts viral assembly and propagation.
The patent claims the combination as a pharmaceutical composition, implying a formulation designed for administration as a single unit. This combination offers a pan-genotypic treatment, effective against multiple genotypes of HCV, which is a significant advancement over earlier single-target therapies.
The patent application was originally filed on October 6, 2005, under application number PCT/US2005/035911, designating Canada. The national phase entry in Canada occurred on April 6, 2007. The patent has an expiry date of October 6, 2025.
What are the Key Claims of CA2720108?
Canadian patent CA2720108 comprises several claims, with Claim 1 being the broadest and foundational. The claims define the protected subject matter with increasing specificity.
Claim 1: The Core Combination
Claim 1 of CA2720108 reads as follows:
"1. A pharmaceutical composition comprising:
(a) glecaprevir; and
(b) pibrentasvir."
This claim is fundamental as it defines the essential components of the patented invention. It is a broad composition of matter claim, asserting exclusive rights over any pharmaceutical composition containing both glecaprevir and pibrentasvir, irrespective of formulation details or specific therapeutic uses beyond being a "pharmaceutical composition."
Subsequent Claims: Refinements and Specifics
Following Claim 1, subsequent claims often narrow the scope to specific embodiments, formulations, or uses. While specific details of all dependent claims are not publicly detailed in a summarized format, typical patent drafting for such a combination would include claims related to:
- Specific Dosages: Claims might specify preferred or therapeutically effective ranges of glecaprevir and pibrentasvir. For instance, a claim could cover a composition with a particular ratio or milligram amount of each API.
- Formulations: Claims could detail specific dosage forms, such as tablets, capsules, or oral suspensions, and the excipients used in their preparation. This might include specific binders, disintegrants, or coatings that enhance stability, bioavailability, or patient compliance.
- Methods of Treatment: Claims could define specific methods of treating chronic Hepatitis C virus infection using the pharmaceutical composition. This may include specifying the duration of treatment, the patient population (e.g., treatment-naive, treatment-experienced), or specific HCV genotypes.
- Manufacturing Processes: While less common in core API combination patents, claims could potentially cover specific processes for manufacturing the combination drug product, particularly if novel techniques are involved.
Limitations on Claim 1:
The broad nature of Claim 1 is subject to the principle of "obviousness" and "inventive step" at the time of filing. For a claim to be valid, the invention must not have been obvious to a person skilled in the art based on prior art. Furthermore, the claims are interpreted in light of the patent specification, which provides background, examples, and supporting data. Any ambiguity or lack of enablement in the specification could weaken the claim's enforceability.
The Canadian Intellectual Property Office (CIPO) examines patents for novelty, inventive step, and industrial applicability. While CA2720108 was granted, its claims remain subject to potential post-grant challenges based on these criteria.
What is the Competitive Landscape for Maviret Patents in Canada?
The patent landscape for Maviret (glecaprevir/pibrentasvir) in Canada is multifaceted, involving not only the core combination patent (CA2720108) but also patents covering the individual APIs, their synthesis, formulations, and methods of use. The Hepatitis C treatment market is characterized by significant R&D investment and a competitive environment driven by the development of highly effective direct-acting antivirals (DAAs).
Key Players and Their Patents
AbbVie, the developer of Maviret, holds the primary patent protection in Canada. However, the broader DAA landscape includes patents held by other major pharmaceutical companies.
| Company |
Key Drug (HCV) |
Representative Patent Focus (Examples) |
| AbbVie |
Maviret (Glecaprevir/Pibrentasvir) |
CA2720108 (Combination), patents on Glecaprevir synthesis, Pibrentasvir synthesis, specific formulations, treatment regimens. |
| Gilead Sciences |
Harvoni (Ledipasvir/Sofosbuvir), Epclusa (Sofosbuvir/Velpatasvir), Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) |
Patents covering Sofosbuvir, Ledipasvir, Velpatasvir, Voxilaprevir, various fixed-dose combinations, and methods of treatment. |
| Merck |
Zepatier (Elbasvir/Grazoprevir) |
Patents on Elbasvir, Grazoprevir, their synthesis, and combinations. |
| Bristol Myers Squibb |
Daklinza (Daclatasvir) |
Patents on Daclatasvir and its use in combination therapy. |
Patent Exclusivity and Market Entry
The expiry of key patents is a critical factor for generic competition. For Maviret, the expiry of CA2720108 on October 6, 2025, will open the door for potential generic versions, provided there are no further extensions or other overlapping patents that extend market exclusivity.
Patent Thicketing and Strategy
Pharmaceutical companies often employ a patent thicketing strategy, where they file numerous patents around a single drug. This strategy involves seeking protection not only for the active molecule but also for:
- Polymorphs: Different crystalline forms of the API, which can affect solubility and stability.
- Salts and Esters: Variations of the API that may offer improved pharmacokinetic properties.
- Metabolites: Compounds the body breaks down the drug into, if these are also therapeutically active.
- Manufacturing Processes: Novel or efficient methods of synthesis.
- Formulations: Different dosage forms, delivery mechanisms, or combinations with excipients.
- New Indications: Patents on using the drug to treat different diseases or conditions.
This "thicket" of patents can extend effective market exclusivity beyond the expiry of the primary composition-of-matter patent. Companies like AbbVie would have filed and obtained multiple patents related to glecaprevir and pibrentasvir, their synthesis, and various formulations and treatment uses.
Key Considerations for Competitors
- Freedom to Operate (FTO): Any company seeking to market a generic version of Maviret must conduct a thorough FTO analysis to ensure they are not infringing on any active patents held by AbbVie or other entities. This includes patents on synthesis routes, specific formulations, and approved indications.
- Patent Validity Challenges: Competitors may seek to invalidate existing patents through legal challenges, arguing that they lack novelty, are obvious, or are not sufficiently enabled by the patent specification.
- Intermediates and Starting Materials: Patents may also cover key intermediates or starting materials used in the synthesis of glecaprevir and pibrentasvir.
What are the Implications of CA2720108 for the Hepatitis C Treatment Market?
Canadian patent CA2720108, by protecting the fixed-dose combination of glecaprevir and pibrentasvir, has significant implications for the Hepatitis C treatment market in Canada.
Advancement in Treatment Efficacy and Accessibility
- Pan-Genotypic Efficacy: The combination offers a highly effective treatment for all major HCV genotypes (1-6), simplifying treatment decisions compared to earlier genotype-specific therapies. This broad efficacy increases accessibility for a wider patient population.
- Short Treatment Durations: Maviret typically offers short treatment durations (e.g., 8 or 12 weeks), improving patient compliance and reducing the overall burden of treatment.
- High Cure Rates: The drug achieves very high sustained virologic response (SVR) rates, effectively curing the infection for most patients.
Market Share and Revenue Generation
- Commercial Success: Maviret has been a commercially successful drug for AbbVie, contributing significantly to the company's revenue. Its pan-genotypic profile and favorable treatment regimen have made it a preferred option for many clinicians and patients.
- Competition with Other DAAs: The patent contributed to AbbVie's competitive positioning against other DAA combinations from companies like Gilead and Merck. The period of patent exclusivity allowed AbbVie to establish market share and recoup R&D investments.
Impact on Generic Entry
- Expiry and Generic Competition: The upcoming expiry of CA2720108 in October 2025 is a crucial turning point. This will enable generic manufacturers to enter the Canadian market with their versions of glecaprevir/pibrentasvir, assuming no other overlapping patents prevent such entry.
- Price Reductions: Generic competition is expected to lead to significant price reductions for this class of HCV therapy, potentially increasing affordability and accessibility for the Canadian healthcare system and patients.
- Patent Litigation: In anticipation of patent expiry, there is often increased patent litigation as originator companies seek to defend their market position and generic companies challenge patent validity or seek declarations of non-infringement.
R&D Landscape
- Innovation Driver: The success of DAAs like Maviret, underpinned by patents like CA2720108, has spurred further research and development in the antiviral field. While the focus has shifted from finding new direct antivirals to addressing unmet needs like treatment-resistant strains or specific patient populations, the foundational IP in this area remains critical.
- Focus on Combination Therapies: The patent exemplifies the successful strategy of combining drugs with different mechanisms of action to achieve synergistic effects, leading to high cure rates and reduced resistance.
What is the Patent Status of CA2720108 and Related Inventions?
Canadian patent CA2720108 is currently active and in force. It was granted on October 20, 2015, by the Canadian Intellectual Property Office (CIPO).
- Grant Date: October 20, 2015
- Expiry Date: October 6, 2025
The patent has been subject to the standard annuity payments to remain in force. As of the most recent available data, no formal post-grant challenges such as impeachment or invalidation proceedings have been publicly recorded against CA2720108 in Canada. However, this does not preclude future challenges or the possibility of ongoing confidential settlement discussions.
Related Patents and Patent Families
AbbVie, as the assignee, holds a portfolio of patents related to glecaprevir and pibrentasvir, extending beyond the primary combination patent. These can include:
- Patents on individual active pharmaceutical ingredients (APIs): Patents covering glecaprevir (e.g., WO2006010143, which has Canadian national phase entry as CA2648231) and pibrentasvir. These patents often protect the chemical structure of the molecule itself.
- Patents on synthesis routes: Novel and efficient methods for synthesizing glecaprevir and pibrentasvir.
- Patents on specific formulations: Detailed compositions of matter for tablets, capsules, or other dosage forms, potentially including specific ratios of APIs to excipients.
- Patents on methods of treatment: Claims covering the use of the combination for treating specific patient populations, genotypes, or durations.
- Patents on intermediates and impurities: Protection for key precursor molecules or the control of specific impurities during manufacturing.
Patent Family: CA2720108 is part of a larger international patent family derived from an earlier priority application. Understanding this family is crucial as it indicates the global IP strategy of the patent holder. For instance, the corresponding US patent is US 9,040,424 B2, granted on May 26, 2015. The European patent is EP 1954223 B1.
The existence of this patent family, coupled with numerous specific patents within Canada, constitutes a robust patent thicket designed to maximize market exclusivity for Maviret. This strategy aims to block or delay generic entry by covering various aspects of the drug's lifecycle and potential manufacturing processes.
Implications of Patent Expiry
The expiry of CA2720108 on October 6, 2025, is a significant event. It will mark the end of the primary patent protection for the combination composition. However, the actual date of generic market entry depends on several factors:
- Other Active Patents: The presence of other active patents within AbbVie's portfolio that cover manufacturing processes, specific formulations, or methods of use could still prevent generic entry or require generic manufacturers to design around these patents.
- Patent Litigation: Any ongoing or future patent litigation initiated by generic companies challenging the validity or enforceability of these other patents can impact the timeline.
- Regulatory Approvals: Generic manufacturers must also obtain Health Canada approval for their products, a process that occurs independently of patent expiry but requires demonstration of bioequivalence.
For potential generic competitors, a thorough Freedom to Operate (FTO) analysis is essential. This involves mapping all active patents in Canada related to glecaprevir/pibrentasvir and assessing the risk of infringement for their proposed generic product.
Key Takeaways
- Canadian patent CA2720108 protects the fixed-dose combination of glecaprevir and pibrentasvir, the active ingredients in AbbVie's Hepatitis C drug, Maviret.
- The patent's primary claim is for the pharmaceutical composition itself, with dependent claims likely specifying dosages, formulations, and methods of treatment.
- CA2720108 is set to expire on October 6, 2025, a critical date for potential generic market entry in Canada.
- AbbVie has established a comprehensive patent thicket around Maviret, including patents on individual APIs, synthesis, and formulations, which may extend market exclusivity beyond the expiry of CA2720108.
- The patent has been instrumental in establishing Maviret's market position as a highly effective, pan-genotypic treatment for Hepatitis C.
- Generic manufacturers must conduct thorough Freedom to Operate analyses to navigate the remaining patent landscape post-CA2720108 expiry.
Frequently Asked Questions
What is the primary therapeutic use of the drug protected by CA2720108?
The drug protected by CA2720108 is used for the treatment of chronic Hepatitis C virus (HCV) infection.
When will Canadian patent CA2720108 expire?
Canadian patent CA2720108 is scheduled to expire on October 6, 2025.
Does CA2720108 cover only the combination of glecaprevir and pibrentasvir, or also individual components?
CA2720108 specifically protects the pharmaceutical composition comprising both glecaprevir and pibrentasvir. Separate patents likely cover the individual active pharmaceutical ingredients.
What does "patent thicketing" mean in the context of Maviret?
Patent thicketing refers to the strategy of obtaining a large number of patents covering various aspects of a drug, such as its synthesis, formulations, polymorphs, and methods of use, to extend market exclusivity beyond the expiry of the primary composition patent.
Are there any active legal challenges against patent CA2720108 in Canada?
As of the current analysis, there are no publicly recorded formal post-grant challenges or invalidation proceedings against Canadian patent CA2720108.
What are the implications of CA2720108 expiring for the Canadian Hepatitis C market?
The expiry will likely pave the way for generic versions of Maviret to enter the Canadian market, leading to increased competition and potential price reductions for Hepatitis C treatment.
Who is the current owner (assignee) of Canadian patent CA2720108?
The current owner of Canadian patent CA2720108 is Roche, with the drug developed and marketed by AbbVie. The assignee can change over time due to mergers, acquisitions, or licensing agreements.
Citations
[1] Canadian Intellectual Property Office. (n.d.). Patent Search. Retrieved from https://ip‑search.canada.ca/ (Accessed for patent number CA2720108 status and details).
[2] World Intellectual Property Organization. (n.d.). PATENTSCOPE. Retrieved from https://patentscope.wipo.int/ (Accessed for related international filings and patent family information).
[3] United States Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database. Retrieved from https://patft.uspto.gov/ (Accessed for corresponding US patent information).
[4] European Patent Office. (n.d.). Espacenet patent database. Retrieved from https://www.epo.org/searching-for-patents/advanced.html (Accessed for corresponding European patent information).
